Nanyang Technological University (NTU) Singapore has unveiled an AI-powered biochip capable of detecting microRNA disease biomarkers in blood samples in just 20 minutes.

This marks a significant leap for diagnostics. Early and rapid detection of disease biomarkers—especially microRNAs—can dramatically improve outcomes for cancer and cardiovascular patients. Traditional detection methods are slow, often taking hours or days and requiring specialized labs. NTU’s new platform reduces this to minutes, potentially transforming how and where diagnostics are performed.

How It Works

The NTU biochip integrates artificial intelligence with microfluidics and biosensors. The AI component analyzes biosensor data in real time, identifying specific microRNA signatures linked to diseases. MicroRNAs are small, non-coding RNA molecules that serve as early indicators for a range of conditions, including several cancers and heart disease.

According to NTU, the chip requires only a small blood sample and delivers results in under 20 minutes—a stark contrast to conventional lab-based assays, which can take several hours and rely on expensive, centralized infrastructure.

Why microRNAs?

MicroRNAs have emerged as a goldmine for early disease detection. Their presence and concentration in blood can signal the onset of disease well before symptoms appear. However, detecting them is technically challenging due to their small size and low abundance. NTU’s biochip addresses this with a combination of sensitive biosensors and AI-driven pattern recognition.

Industry Context

The fusion of AI and biosensing is not new, but NTU’s approach is notable for its speed and specificity. Rapid diagnostics is a hotbed for health-tech innovation, with startups and incumbents vying to bring point-of-care testing closer to the patient. The global point-of-care diagnostics market is projected to reach $68.6 billion by 2030, according to Grand View Research. AI-enabled platforms are expected to capture a growing share of that market, especially as personalized medicine gains traction.

NTU’s biochip is positioned to support personalized medicine by enabling quick, precise biomarker profiling. This could allow clinicians to tailor treatments in near real-time, rather than waiting days for lab results.

What’s Next?

The NTU team is now focused on clinical validation and scaling up production. While the biochip is still in the research phase, its potential for rapid, decentralized diagnostics is clear. If commercialized, it could disrupt not just hospital labs but also primary care, telemedicine, and even at-home testing.

Key Data: 20-minute detection time; targets microRNA biomarkers; developed by NTU Singapore.

For founders, investors, and health-tech strategists, this is a signal: AI-driven biosensing is moving out of the lab and into the clinic—and the race to own the diagnostic workflow is accelerating.

What This Means

For founders, NTU’s breakthrough is both a challenge and an opportunity. The bar for diagnostic speed and accuracy just got higher. Startups in the biomarker and point-of-care space will need to match or exceed these benchmarks, or risk irrelevance as AI-biosensor integration becomes the norm.

For the industry, this signals a shift toward decentralized, real-time diagnostics. Hospitals and clinics may soon expect near-instant biomarker results as standard, upending traditional lab workflows and creating new demand for AI-powered platforms. The next battleground: regulatory approval and integration into existing healthcare systems, where speed can clash with safety and reimbursement realities.

The non-obvious effect? As detection gets faster and more accessible, the bottleneck may shift from diagnosis to treatment logistics and patient follow-up. Expect a ripple effect across care pathways, with AI-driven triage and personalized medicine moving from buzzwords to baseline expectations.